Ikarian Capital, LLC Cara Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$11.55 - $16.06 $338,819 - $471,120	-29,335 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$12.38 - $29.19 $6.55 Million - $15.4 Million	-529,189 Reduced 94.75%	29,335 $418,000
Q1 2021 May 17, 2021	BUY	$15.07 - $21.71 $4.29 Million - $6.19 Million	285,000 Added 104.2%	558,524 $12.1 Million
Q2 2020 Aug 14, 2020	SELL	$12.39 - $17.33 $3.45 Million - $4.83 Million	-278,639 Reduced 50.46%	273,524 $4.68 Million
Q1 2020 May 15, 2020	BUY	$9.12 - $17.78 $5.04 Million - $9.82 Million	552,163 New	552,163 $7.29 Million

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $16.7M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.